New Israeli study finds vaccinating all toddlers against hepatitis A

December 19, 2005

Results from a new study presented today found that vaccinating all children against hepatitis A at 18 and 24 months in one Israeli community reduced overall incidence of the disease for all ages by 95 percent. The study, authored by Ron Dagan, M.D., Director of the Pediatric Infectious Disease Unit at Soroka University Medical Center, Be'er Sheva, Israel, was presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Experts have long believed that universal hepatitis A vaccination for children is an effective strategy to reduce disease incidence. This study coincides with the recent unanimous decision of the Advisory Committee on Immunization Practices (ACIP), an advisory body to the Centers for Disease Control and Prevention (CDC), recommending universal hepatitis A vaccination for all children between one and two years of age. The ACIP recommendation marks a milestone in the fight against the disease in the United States, particularly among toddlers who play an important role in hepatitis A transmission.

Entitled "Universal Toddler Hepatitis A Virus Vaccination: An Opportunity for the Elimination of Population Disparity in Disease Incidence," the study by Dr. Dagan highlights the fact that before vaccination, one-fifth of all toddlers in a hepatitis A endemic community had high hepatitis A antibody levels indicating previous exposure. This was reduced by 90 percent within three years after initiation of the toddler-only universal vaccination program. In addition, a distinct disparity in hepatitis disease incidence between the Jewish and non-Jewish population, related to differences in social and economic living conditions, was practically eliminated, due to a very impressive reduction in disease in both populations following vaccination.

"This study demonstrates the significant impact the hepatitis A vaccine can have on the overall population," said Dr. Dagan. "Vaccinating all toddlers not only resulted in a dramatic reduction of hepatitis A incidence in an age group in Israel vulnerable to the disease, but also offers objective proof of the rapid vaccination-induced reduction of hepatitis A circulation, and the positive effect vaccination can have, on that community."

The study presented by Dr. Dagan follows the fluctuation in hepatitis A incidence rates among the Israeli population. Since 1999, coinciding with the introduction of the hepatitis A vaccine to all toddlers at 18 and 24 months, overall levels of hepatitis A incidence have been reduced by 95 percent, supporting the belief that the immunization of toddlers in the 18 to 24 month bracket confers "herd immunity," the protection extended to family members and the community in general when a large portion of a population is vaccinated. In addition, the most significant decrease in hepatitis A levels after the introduction of hepatitis A immunization in toddlers was seen in the one to four year age bracket - a demographic that is historically the most susceptible to this type of infection. There was almost 100 percent (98.5 percent) decrease in reported incidences among this demographic.

These findings are consistent with the recent study by Wasley et al ("Incidence of Hepatitis A in the United States in the Era of Vaccination," Journal of American Medical Association, July 13, 2005) which shows sustaining and further reducing hepatitis A incidences in the United States can be achieved by improving vaccination coverage in groups for which it is currently recommended. Similar to the Israeli study, Wasley et al found that a decline in hepatitis A infection rates in children occurred with the mandated vaccination of one age group and helped reduce transmission in other age groups, supporting the hypothesis of a strong herd immunity effect. Wasley et al concluded that elimination of hepatitis A would require expansion of current recommendations to include routine vaccination of all children. The unanimous ACIP decision to recommend incorporating hepatitis A vaccination into the children's immunization schedule reinforces the need to improve and enhance the health and well-being of children by helping to protect them from this serious and highly contagious disease.
About Hepatitis A

Hepatitis A is a serious liver disease caused by the hepatitis A virus. This virus is found in the stool of persons with hepatitis A and is spread by close personal contact and by eating food or drinking water contaminated with the hepatitis A virus. About one in five people with the disease have to be hospitalized and up to 100 people with the disease may die each year in the U.S. Symptoms of the disease can be debilitating and include fever, fatigue, loss of appetite, nausea, abdominal discomfort, jaundice and dark urine.

GlaxoSmithKline provided editorial and media relations assistance for this release.

Cohn & Wolfe

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to